Your session is about to expire
← Back to Search
Daratumumab Combination Therapy for Multiple Myeloma
Study Summary
This trial tests whether adding daratumumab to standard myeloma treatment is safe and improves outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 1 & 2 trial • 22 Patients • NCT02841033Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am using birth control and have had a recent negative pregnancy test.My health status meets specific criteria related to blood, bone, kidney, liver conditions, and my physical ability.I do not have specific conditions like uncontrolled diabetes, heart disease, or recent major surgery.You have a specific type of disease that has been measured within the past 4 weeks using specific tests for proteins in the blood and urine, as well as any related organ damage.I have received more than one cycle of treatment for multiple myeloma.I agree to use a latex condom during sex with a female capable of becoming pregnant.My condition has caused damage to my organs or significant health events due to a plasma cell disorder.I have been recently diagnosed with multiple myeloma.I have followed the required break period after my last treatment.
- Group 1: Cohort 1
- Group 2: Cohort 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the efficacy of daratumumab been tested in other clinical trials?
"Research into daratumumab began in 2002 at Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. To date, 1391 studies have been concluded and a further 752 are still ongoing, many of which are being conducted from Commack, New jersey."
What diseases does daratumumab typically serve to remedy?
"Ophthalmia, sympathetic can often be managed through the use of daratumumab. Additionally, this drug has also been found to treat branch retinal vein occlusion, macular edema and those who have already undergone two rounds of systemic chemotherapy."
How many health facilities are conducing this clinical research?
"As it stands, 7 medical facilities are hosting this particular trial. These sites can be found in Commack, Middletown and Basking Ridge as well other cities around the US. To make participation easier on you, try to select a location closest your current residence or place of work."
Are there any open spots in this experiment at the present moment?
"No longer recruiting, this trial was initially posted on September 25th 2017 and last updated November 17 2022. Currently, there are 807 studies involving multiple myeloma accepting patients as welll as 752 trials for participants with daratumumab."
Does the administration of daratumumab confer any risks to humans?
"Daratumumab has been judged to have a safety rating of 2. This is because while there are some data points that demonstrate its safety, efficacy remains unconfirmed as this trial only just entered Phase 2."
What is the enrollment rate for this trial's participants?
"As of November 17th 2022, this trial has stopped accepting new patients. It first appeared on September 25 2017 and was last updated a few weeks ago. If you are interested in similar studies though, 807 trials for multiple myeloma and 752 for daratumumab are still enrolling participants."
Share this study with friends
Copy Link
Messenger